×
0 0 0 0 0 0 0 0
Stockreport

Akebia Therapeutics Provides Update on Vadadustat Development Program

AKEBIA THERAPEUTICS (AKBA)  More Company Research Source: Business Wire
Last akebia therapeutics earnings: 11/8 04:05 pm Check Earnings Report
PDF -- Targets Full Enrollment for INNO2VATE and PRO2TECT by the End of 2018 -- -- Confirms Expectation of Top-Line Results for INNO2VATE and PRO2TECT in 2019, Subject to Accrual of MACE Events -- -- Enhances FO2RWARD and TRILO2GY Study Designs for Commercial Optimization -- -- Confirms No Carcinogenic Effect in Two Non-Clinical Carcinogenicity Studies -- -- Partner Mitsubishi Tanabe Pharma Corporation Initiates Phase 3 NDD-CKD and DD-CKD Program in Japan -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today provided an update on the global development plan for vadadustat, an oral HIF stabilizer in global Phase 3 development for the treatment of anemia due to chronic kid [Read more]

IMPACT SNAPSHOT EVENT TIME: AKBA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS